Citations

Clear

12 citation(s) found for "Schnitt, Stuart".

World Health Organization classification of tumours of the breast 6th edition 2026
Quinn, Cecily , Tan, Puay Hoon , Allison, Kimberly H. , Brogi, Edi , Lakhani, Sunil R. , Schnitt, Stuart J. , Fox, Stephen B. , Jaffer, Shabnam , Şahin, Ayşegül A. , Salgado, Roberto , Adjei, E, Helbich, Thomas H. , Sotiriou, C, Hodge, Jennelle C. , Khoury, Joseph D. , Puspanathan, Pavitratha, Giesen, Christine, Ruiz, Blanca Iciar Indave , Ellis, Ian, Lokuhetty, Dilani , Board, WCT Standing Editorial, Netto, George J. , Sahin, Aysegul , Sapino, Anna , Adjei, Ernest Kwasi , Geiersbach, Katherine , Helbich, Thomas H , Lambertini, Matteo , Sotiriou, Christos P. , Hodge, Jennelle C , Khoury, Joseph , Rekhi, Bharat , Ryska, Ales , Tse, Gary , Field, Andrew , Wijesinghe, Harshima , Puspanathan, Pavitratha , Giesen, Christine , Ruiz, Blanca Iciar Indave , Ellis, Ian , Lokuhetty, Dilani , Geiersbach, Katherine B. , Lambertini, Matteo , Field, Andrew , Ellis, Ian O. , board, WCT standing editorial

Mayo Clinic

Histopathology | April 21, 2026 | Volume: 89 | Issue: 2 | Pages: 199-218

10.1111/his.70149 | PMID 42011085 Get It

The 6th edition of the WHO Classification of Breast Tumours introduces both major and minor changes based on recent advances in our understanding of breast biology, developments in diagnostic modalities, identification of specific molecular targets and new treatment regimens necessitating modifications to pathology reporting and tumour biomarker categorisation. This review summarises the main changes that strive towards a classification of global relevance. In invasive carcinoma, predictive factors increasingly inform modern breast cancer treatment. The 6th edition provides an update on HER2 reporting categories following the DESTINY‐Breast 04 and 06 trials. Terminologies used to classify invasive tumours are clarified, with the term ‘variant’ now reserved for molecular/genetic alterations. Invasive lobular carcinoma (ILC) with extracellular mucin is recognised as a new diagnostic entity with prognostic implications. The diagnosis of mucinous carcinoma (MC) is reserved for mucin secreting carcinomas with grade 1 or 2 morphology and a favourable biomarker profile. The diagnosis of malignant phyllodes tumours requires only four of the original five adverse histological criteria. Classification of neuroendocrine tumours (NETs) is revised, recognising that the unified model, promoted in the 5th edition, is difficult to apply to the breast. New approaches to the classification of adenomyoepithelioma are discussed but the 5th edition system is broadly retained. A new section on ‘Small Diagnostic Samples’ outlines the merits of non‐operative biopsy diagnosis, the B coding system and the importance of multidisciplinary review. Changes to diagnostic practice and the emerging role of artificial intelligence, with advantages and challenges, are discussed in a new section on ‘Digital Pathology’.
Abstract 7903: MiR-362-3p enhances platinum response in breast cancer
Liu, Zhaoji, Ke, Shizhong, Li, Xiaohui, Wu, C., Uyemura, Madison M., Sardella, Barbara, Massicott, Erica S., Wang, Lin, Aronson, Emily K., Karagkouni, Dimitra, Kalavros, Nikolaos , Bogsan, Cristina S, Zhou, Lihan, Cheng, He, Garber, J. E., Schnitt, Stuart J. , Tung, Nadine M., Wulf, G. M., Heng, Yujing J., Ke, Shizhong, Li, Xiaohui, Wang, Lin , Aronson, Emily K., Karagkouni, Dimitra , Vlachos, Ioannis S. , Batalini, Felipe , Bogsan, Cristina Stewart Bittencourt , Cheong, Jit Kong , Cheng, He, Munson, Phillip B. , Mayer, Erica L. , Tung, Nadine , Kasinski, Andrea L. , Slack, Frank John , Wulf, Gerburg M. , Heng, Yujing J.

Mayo Clinic

Cancer Research | April 3, 2026 | Volume: 86 | Issue: 7_Supplement | Pages: 7903-7903

10.1158/1538-7445.am2026-7903 Get It

Abstract The INFORM trial (NCT01670500) was a randomized, two-arm Phase II neoadjuvant study comparing the efficacy of a platinum-based regimen (cisplatin) versus an anthracycline (AC)-based regimen in participants with germline BRCA1/2 mutations and early-stage, HER2-negative breast cancer. MicroRNAs (miRNAs) are emerging as promising non-invasive biomarkers for disease detection and treatment monitoring. The initial aim of this study was to evaluate whether pretreatment plasma miRNA profiles were associated with treatment outcomes in the INFORM trial cohort. Pretreatment plasma samples from 97 INFORM participants (n=53 cisplatin and n=44 AC) were screened for 352 miRNAs commonly implicated in cancer using the qPCR-based ID3EALTM Cancer Panel. Twenty out of 53 participants achieved residual cancer burden (RCB) score of 0 or 1 with cisplatin and 20/44 with AC. Higher plasma miR-362-3p expression was associated with a favorable response to cisplatin (1.7-fold; p<0.01), but not to AC. MiR-362-3p expression in paired pretreatment tumor biopsies (n=79) did not significantly correlate with plasma expression and was not associated with RCB 0/1 (p>0.05). In TCGA, miR-362-3p expression was higher in breast tumors than in adjacent normal tissue, and higher in triple negative breast cancers (TNBCs) compared with hormone receptor-positive tumors (both FDR<0.001), independent of BRCA mutation or Single Base Substitution Signature 3 (SBS3) status. The miR-362-3p findings in INFORM did not replicate in a sister trial, TBCRC 030 (NCT01982448; 11 out of 46 cisplatin-treated patients achieved RCB 0/1, p=0.46). These results suggest that while miR-362-3p is unsuitable as a circulating biomarker for cisplatin response, it may play an important biological role in mediating cisplatin sensitivity in TNBCs, independent of BRCA1/2 mutations. Functional studies demonstrated that miR-362-3p is expressed and secreted by TNBC cell lines, operates as a tumor suppressor, and generally correlates with cisplatin sensitivity. Overexpression of miR-362-3p rendered MDA-MB-231 and CAL-51 cells cisplatin sensitive, while knockdown induced resistance in MDA-MB-436 cells. Ongoing studies are testing whether these effects translate in xenograft models. In silico and functional assays identified BCLAF1, a DNA damage response (DDR) regulator, as a direct target of miR-362-3p. Overexpression of miR-362-3p suppresses BCLAF1 mRNA and protein levels. Our findings demonstrate that miR-362-3p enhances cisplatin responsiveness by targeting BCLAF1. A miR-362-3p-based therapeutic may be useful as a co-agent to enhance tumor responses to platinum-based chemotherapy. Citation Format: Zhaoji Liu, Shizhong Ke, Xiaohui Li, Catherine Wu, Madison M. Uyemura, Brian R. Sardella, Erica S. Massicott, Lin Wang, Emily K. Aronson, Dimitra Karagkouni, Nikolas Kalavros, Ioannis S. Vlachos, Felipe Batalini, Cristina S. Bogsan, Jit Kong Cheong, Lihan Zhou, He Cheng, Phillip Munson, Erica L. Mayer, Judy E. Garber, Stuart J. Schnitt, Nadine M. Tung, Andrea L. Kasinski, Frank J. Slack, Gerburg M. Wulf, Yujing J. Heng. MiR-362-3p enhances platinum response in breast cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 7903.
The miR-362-3p/ BCLAF1 axis regulates cisplatin sensitivity and metastatic progression in triple-negative breast cancer
Liu, Zhaoji, Wu, Catherine, Uyemura, Madison M., Sardella, Barbara, Aronson, Emily K, Ke, Shizhong, Massicott, Erica S., Li, Xiaohui, Wang, Lin, Karagkouni, Dimitra, Kalavros, Nikolaos , Bogsan, Cristina S, Zhou, Lihan, Cheng, He, Garber, Judy E, Schnitt, Stuart J. , Tung, Nadine M, Heng, Yujing J., Heng, Yujing J. , Wu, C., Aronson, Emily K., Ke, Shizhong, Li, Xiaohui, Wang, Lin , Karagkouni, Dimitra , Vlachos, Ioannis S. , Batalini, Felipe , Bogsan, Cristina Stewart Bittencourt , Cheong, Jit Kong , Munson, Phillip B. , Mayer, Erica L. , Garber, Judy E. , Tung, Nadine , Kasinski, Andrea L. , Slack, Frank John , Wulf, Gerburg M.

Mayo Clinic

No container title available | March 11, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.03.09.26347941 Get It

Abstract Platinum-based chemotherapy remains a cornerstone of treatment for triple-negative breast cancer (TNBC), yet the molecular determinants governing platinum response remain poorly defined. By leveraging the randomized Phase II INFORM trial, which compared neoadjuvant cisplatin to anthracycline-based therapy in BRCA1/2 -mutant breast cancer—we identified miR-362-3p as a specific regulator of cisplatin sensitivity. Higher plasma miR-362-3p expression was exclusively associated with favorable clinical outcome in the cisplatin arm, with no association observed in the AC arm, decoupling platinum-specific vulnerability from general chemotherapy response. We used gain- and loss-of-function TNBC models to establish that miR-362-3p functions as a potent sensitizer to cisplatin in vitro and in vivo . Integrated TCGA analysis and experimental validation identified BCLAF1, a key regulator of DNA damage response, as a direct repression target of miR-362-3p. We uncovered a novel role for the miR-362-3p/ BCLAF1 axis in overcoming platinum resistance in TNBC.
ETHAN: A phase II study comparing different endocrine therapies for male breast cancer.
Leone, José Pablo , Ruddy, Kathryn J. , Rashid, Naim U. , Ortiz-Perez, Tamara, Abdou, Yara, Sharpe, Jessica Mezzanotte, McAuliffe, Priscilla F., Park, Ben Ho, Quintana, Liza M., Schnitt, Stuart J., Krop, Ian E. , Thompson, Alastair M. , Sukumar, Jasmine S , Giordano, Sharon H. , Gupta, Gaorav P , Hilsenbeck, Susan Galloway , Walsh, Elaine M. , Makhlin, Igor , Abdou, Yara, Sharpe, Jessica Mezzanotte, McAuliffe, Priscilla F., Park, Ben Ho, Quintana, Liza M., Schnitt, Stuart J., Spanheimer, Philip M. , Wolff, Antonio C.

Mayo Clinic

Journal of Clinical Oncology | May 29, 2024 | Volume: 42 | Issue: 16_suppl | Pages: TPS632-TPS632

10.1200/jco.2024.42.16_suppl.tps632 Get It

TPS632 Background: Male breast cancer is a rare disease, and most cases are hormone receptor-positive (HR+). Due to a lack of clinical trials, male breast cancer has historically been treated based on data extrapolated from women. However, there are substantial knowledge gaps in the comparative efficacy, safety, and patient-reported outcomes of endocrine therapies for male breast cancer. While tamoxifen is the current standard of care, additional data are warranted for aromatase inhibitors (AI), gonadal suppression, and cyclin-dependent kinase 4/6 (CDK4/6) inhibitors. Methods: This is an open-label, multicenter, randomized, phase II trial designed to evaluate different endocrine therapies in men with HR+ and human epidermal growth factor receptor 2 (HER2)-negative breast cancer. A total of 60 men will be enrolled across nine (9) sites within the Translational Breast Cancer Research Consortium (TBCRC). Key eligibility criteria include male sex and stage I, II, or III HR+/HER2- breast cancer before surgical resection of the primary tumor and axillary nodes. Key exclusion criteria include prior anti-cancer therapy for the current breast cancer or any other malignancy within the past 12 months, and inflammatory breast cancer. The trial has two phases. The first phase is a window of opportunity component in which newly diagnosed men are randomized 1:1:1 to either tamoxifen (Arm A), anastrozole (Arm B), or anastrozole plus degarelix (Arm C) given for three weeks. The primary endpoint for the window phase is Ki-67 reduction from the baseline diagnostic biopsy to the research biopsy at the end of the window phase. The second phase consists of neoadjuvant treatment, in which the tamoxifen group is randomized 1:1 to tamoxifen (Arm D) versus tamoxifen plus abemaciclib (Arm E), and the anastrozole alone (Arm B) and anastrozole plus degarelix (Arm C) groups are merged and then randomized 1:1 to anastrozole plus degarelix (Arm F) versus anastrozole plus degarelix plus abemaciclib (Arm G). The duration of the neoadjuvant phase is four (4) months, and the primary endpoint of this phase is residual cancer burden (RCB) index at time of surgery. The trial is powered for the RCB endpoint in a 2 x 2 factorial design to detect a 0.6 unit decrease in RCB index with 80% power and alpha=10%. For the Ki-67 endpoint, we assume an approximately 50% reduction in Arms A and B; Arm C will be of interest if it leads to ≥80% reduction in Ki-67. Secondary endpoints include: estradiol and testosterone levels at baseline, end of window, and during neoadjuvant phase; preoperative endocrine prognostic index (PEPI) score at surgery; adverse events; and patient-reported outcomes (including quality of life). Tumor tissue will be collected for correlative analyses. The study opened to enrollment at Dana-Farber in October 2023, and additional sites will open in 2024. Clinical trial information: NCT05501704 .
Identification of Glandular (Acinar)/Tubule Formation in Invasive Carcinoma of the Breast: A Study to Determine Concordance Using the World Health Organization Definition
Lo, Yungtai , Lester, Susan C. , Lanjewar, Sonali, Laurini, Javier A., Patel, Ami , Bhattarai, Ava, Ustun, Berrin , Harmon, Bryan, Kleer, Celina G. , Ross, Dara S. , Amin, Ali , Wang, Yihong , Bradley, Robert, Turashvili, Gulisa , Zeng, Jennifer , Baum, Jordan , Hakima, Laleh , Harigopal, Malini, Shin, Sandra J. , Abbott, Sara, Jaffer, Shabnam , Badve, Sunil Shankar, Khoury, Thaer , D’Alfonso, Timothy M. , Collins, Victoria , Towne, William S. , Gan, Yujun, Flieder, Andrea, Aldrees, Rana, Ngo, Marie-Hélène , Edema, Ukuemi, Sapna, Fnu , Schnitt, Stuart J. , Fineberg, Susan , Komforti, Miglena, Wang, Yihong , Turashvili, Gulisa , Ellis, Ian O. , Singh, Kamaljeet , Komforti, Miglena K. , Badve, Sunil , Ginter, Paula S. , Nassar, Aziza , Şahin, Ayşegül A.

Mayo Clinic

Archives of Pathology & Laboratory Medicine | January 20, 2024 | Volume: 148 | Issue: 10 | Pages: 1119-1125

10.5858/arpa.2023-0163-oa | PMID 38244086 Get It

Context.— The Nottingham Grading System (NGS) developed by Elston and Ellis is used to grade invasive breast cancer (IBC). Glandular (acinar)/tubule formation is a component of NGS. Objective.— To investigate the ability of pathologists to identify individual structures that should be classified as glandular (acinar)/tubule formation. Design.— A total of 58 hematoxylin-eosin photographic images of IBC with 1 structure circled were classified as tubules (41 cases) or nontubules (17 cases) by Professor Ellis. Images were sent as a PowerPoint (Microsoft) file to breast pathologists, who were provided with the World Health Organization definition of a tubule and asked to determine if a circled structure represented a tubule. Results.— Among 35 pathologists, the κ statistic for assessing agreement in evaluating the 58 images was 0.324 (95% CI, 0.314–0.335). The median concordance rate between a participating pathologist and Professor Ellis was 94.1% for evaluating 17 nontubule cases and 53.7% for 41 tubule cases. A total of 41% of the tubule cases were classified correctly by less than 50% of pathologists. Structures classified as tubules by Professor Ellis but often not recognized as tubules by pathologists included glands with complex architecture, mucinous carcinoma, and the “inverted tubule” pattern of micropapillary carcinoma. A total of 80% of participants reported that they did not have clarity on what represented a tubule. Conclusions.— We identified structures that should be included as tubules but that were not readily identified by pathologists. Greater concordance for identification of tubules might be obtained by providing more detailed images and descriptions of the types of structures included as tubules.
Abstract P5-12-03: Intratumor heterogeneity and intrinsic immune activation are associated with response to chemotherapy in BRCA-related breast cancers
Katopodi, Xanthi Lida, Kalavros, Nikolaos , Tran, Antuan V. , Karagkouni, Dimitra , Stern-Gatof, Emily, Schnitt, Stuart J. , Vlachos, Ioannis S. , Tung, Nadine, Vlachos, Ioannis S , Batalini, Felipe , Gulhan, D. , Katopodi, Xanthi-Lida , Garber, Judy E. , Wulf, Gerburg M. , Park, Peter J. , Tung, Nadine

Mayo Clinic

Cancer Research | March 2, 2023 | Volume: 83 | Issue: 5_Supplement | Pages: P5-12-03-P5-12-03

10.1158/1538-7445.sabcs22-p5-12-03 Get It

Abstract Background Breast cancers in women with a germline BRCA1/2 mutation (gBRCAm) have homologous recombination deficiency (HRD) and are sensitive to therapies causing double-strand DNA breaks. In TBCRC 031 (INFORM), both neoadjuvant cisplatin and doxorubicin/cyclophosphamide (“AC”) in gBRCAm carriers resulted in a complete pathologic response in 18% and 26% respectively in patients with newly diagnosed HER2–negative breast cancer. Herein, we describe molecular features from tumor whole exome (WES) and transcriptome sequencing (RNAseq) associated with response. Methods TBCRC 031 (the INFORM Trial - NCT01670500) was a randomized phase II neoadjuvant trial comparing the efficacy of cisplatin versus AC in gBRCAm carriers with stage I-III HER2–negative breast cancer. Of 118 patients enrolled, 92 patients provided fresh frozen research biopsies, collected prior to chemotherapy initiation, which were subjected to WES and RNAseq. Variants were called using GATK best practices and intratumoral heterogeneity was inferred from mutations and variant allele frequencies using Mutant Allele Tumor Heterogeneity (MATH) scores. Mutational Signature 3 (Sig3) and Genomic Instability Score (GIS) were calculated with SigMA and scarHRD, respectively. RNAseq data were utilized to perform differential gene expression and functional analyses, while cellular deconvolution was performed with CIBERSORTx trained against breast cancer single cell data. Patients were grouped according to their residual cancer burden (RCB) as responders (RCB-0 or 1), or non-responders (RCB-2 or 3). P-values ≤ 0.05 were considered statistically significant and when appropriate, adjustment for multiple testing was performed using a false discovery rate ≤ 5%. Results Of the 92 patients with gBRCAm, 59 (64%) had triple-negative and 33 (36%) were hormone-receptor positive HER2-negative breast cancer, 40 (43%) were classified as responders and 52 (57%) as non-responders. WES analysis revealed that indices of HRD were high (Sig3 exposure predominant and GIS ≥ 42) across most samples irrespective of receptor status and not significantly different among responders and non-responders. In contrast, responders exhibited lower levels of intratumor heterogeneity than non-responders (median MATH 42.9 vs. 33.5, p = 0.01). 223 genes were differentially expressed between responders and non-responders following control for tumor hormone receptor status, BRCA1/2 mutation, and menopausal status. Pathways identified as significantly enriched in upregulated genes were indicative of intrinsic immune activation in responders (e.g., T-cell activation, immune response-signaling, and regulation of leukocyte activation). Cellular deconvolution of the tumor microenvironment confirmed that responders presented a higher proportion of T-cells (p = 0.025) and myeloid cells (p = 0.003) in the tumor samples, while perivascular-like cells were enriched in non-responders (p = 0.034). Conclusion In this analysis of the largest cohort of treatment-naïve gBRCAm breast cancer to date, we found that response to cytotoxic chemotherapy is associated with a transcriptional program of intrinsic immune activation and an increased population of intratumoral T-cells and myeloid cells. Lower levels of intratumor heterogeneity and higher immune activation were associated with response to chemotherapy gBRCAm carriers while HRD scores were not. Citation Format: Felipe Batalini, Doga C. Gulhan, Xanthi Lida Katopodi, Nikolas Kalavros, Antuan Tran, Dimitra Karagkouni, Emily Stern-Gatof, Stuart Schnitt, Judy E. Garber, Gerburg M. Wulf, Peter J. Park, Ioannis Vlachos, Nadine Tung. Intratumor heterogeneity and intrinsic immune activation are associated with response to chemotherapy in BRCA-related breast cancers [abstract]. In: Proceedings of the 2022 San Antonio Breast Cancer Symposium; 2022 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2023;83(5 Suppl):Abstract nr P5-12-03.
The path to a better biomarker: application of a risk management framework for the implementation of PD‐L1 and TILs as immuno‐oncology biomarkers in breast cancer clinical trials and daily practice
González-Ericsson, Paula I. , Stovgaard, Elisabeth Specht , Reisenbichler, Emily , Kos, Zuzana , Carter, Jodi M. , Michiels, Stefan , Quesne, John Le , Lænkholm, Anne‐Vibeke , Adam, Julien , Bartlett, John MS, Rimm, David L. , Quinn, Cecily , Cree, Ian A. , Hida, Akira I. , Haynes, Harry R. , Frahm, Isabel, Acosta‐Haab, Gabriela, Balancin, Marcelo Luiz , Bellolio, Enrique , Yang, Wentao , Kirtani, Pawan , Sugie, Tomoharu , Ehinger, Anna , Castaneda, Carlos, Kok, Marleen , McArthur, Heather L. , Siziopikou, Kalliopi P. , Fineberg, Susan , Gown, Allen M. , Viale, Giuseppe , Schnitt, Stuart J. , Pruneri, Giancarlo , Penault‐Llorca, Frederique, Hewitt, Stephen M. , Thompson, E. Aubrey , Allison, Kimberly H. , Symmans, W. Fraser , Bellizzi, Andrew M. , Brogi, Edi , Moore, David A. , Larsimont, Denis , Dillon, Deborah , Broeckx, Glenn , Bairi, Khalid El , Cimino‐Mathews, Ashley , Adams, Sylvia , Liu, S, Loibl, Sibylle , Chen, I‐Chun , Juco, Jonathan, Blackley, Elizabeth F. , Demaria, Sandra , Leon‐Ferre, Roberto A. , Zardavas, Dimitrios, Emancipator, Kenneth , Ely, Scott , Loi, Sherene , Salgado, Roberto , Group, International Immuno‐Oncology Biomarker Working, Cree, Ian , Haynes, Harry R , Balancin, Marcelo , Ehinger, Anna , Lazar, Alexander J , Broeckx, Glenn , El Bairi, Khalid , Leon-Ferre, Roberto, Gonzalez-Ericsson, Paula I , Bellizzi, Andrew M , Symmans, W Fraser , Loi, Sherene , Pruneri, Giancarlo , Rimm, David , Carter, Jodi , Sua, Luz Fernanda , Nielsen, Torsten O. , Fox, Stephen B. , Bartlett, John MS, Peeters, Dieter J. E. , Dieci, Maria Vittoria , Vincent‐Salomon, Anne , Balko, Justin M. , Badve, Sunil , Penault-Llorca, Frederique Madeleine , Lazar, Alexander J. , Lien, Huang‐Chun , Goetz, Matthew P. , Harbeck, Nadia , Sotiriou, Christos P. , Lakhani, Sunil R. , Denkert, Carsten , Gluz, Oleg , Sanders, Melinda E. , Group, International Immuno‐Oncology Biomarker Working

Mayo Clinic

The Journal of Pathology | March 4, 2020 | Volume: 250 | Issue: 5 | Pages: 667-684

10.1002/path.5406 | PMID 32129476 Get It

AbstractImmune checkpoint inhibitor therapies targeting PD‐1/PD‐L1 are now the standard of care in oncology across several hematologic and solid tumor types, including triple negative breast cancer (TNBC). Patients with metastatic or locally advanced TNBC with PD‐L1 expression on immune cells occupying ≥1% of tumor area demonstrated survival benefit with the addition of atezolizumab to nab‐paclitaxel. However, concerns regarding variability between immunohistochemical PD‐L1 assay performance and inter‐reader reproducibility have been raised. High tumor‐infiltrating lymphocytes (TILs) have also been associated with response to PD‐1/PD‐L1 inhibitors in patients with breast cancer (BC). TILs can be easily assessed on hematoxylin and eosin–stained slides and have shown reliable inter‐reader reproducibility. As an established prognostic factor in early stage TNBC, TILs are soon anticipated to be reported in daily practice in many pathology laboratories worldwide. Because TILs and PD‐L1 are parts of an immunological spectrum in BC, we propose the systematic implementation of combined PD‐L1 and TIL analyses as a more comprehensive immuno‐oncological biomarker for patient selection for PD‐1/PD‐L1 inhibition‐based therapy in patients with BC. Although practical and regulatory considerations differ by jurisdiction, the pathology community has the responsibility to patients to implement assays that lead to optimal patient selection. We propose herewith a risk‐management framework that may help mitigate the risks of suboptimal patient selection for immuno‐therapeutic approaches in clinical trials and daily practice based on combined TILs/PD‐L1 assessment in BC. © 2020 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
Pan-TRK Immunohistochemistry
Harrison, Beth , Fowler, Elizabeth , Krings, Gregor , Chen, Yunn-Yi, Bean, Gregory R. , Fuhrmann, Laetitia , Barnick, Sandra E., Chen, Beiyun, Hosfield, Elizabeth M., Schnitt, Stuart J. , Fowler, Elizabeth, Chen, Yunn‐Yi , Vincent‐Salomon, Anne , Hornick, Jason L.

Mayo Clinic

American Journal of Surgical Pathology | September 9, 2019 | Volume: 43 | Issue: 12 | Pages: 1693-1700

10.1097/pas.0000000000001366 | PMID 31498178 Get It

Secretory carcinoma is a special-type breast carcinoma underpinned by a recurrent t(12;15)(p13;q25) translocation resulting in ETV6-NTRK3 gene fusion. Immunohistochemistry (IHC) using a pan-TRK antibody has been recently shown to help identify NTRK rearrangements in other tumor types. The purpose of this study was to assess the diagnostic utility of pan-TRK IHC in secretory carcinoma of the breast. Pan-TRK IHC was performed using a rabbit monoclonal antibody on whole sections of 24 breast secretory carcinomas and tissue microarray sections of other breast carcinoma types (n=203) and histologic mimics (n=15). Cases were assessed for staining intensity and localization. The 24 patients with secretory carcinoma had a median age of 44 years and a median tumor size of 1.0 cm. ETV6 fluorescence in situ hybridization was positive in all cases tested (n=20). Twenty-three cases (95.8%) showed staining with pan-TRK, which was exclusively nuclear in 19, primarily nuclear with weak cytoplasmic staining in 3, and primarily cytoplasmic with focal nuclear staining in 1. The nuclear staining was diffuse in 17 and at least focally strong in 17. The only pan-TRK negative case was a core biopsy with limited tumor. Among the 203 nonsecretory carcinomas, 21 (10.3%) showed focal, weak nuclear staining in <5% of tumor cells and 1 (0.5%) showed focal membranous staining. All histologic mimics were negative. In conclusion, diffuse and/or at least focally strong nuclear pan-TRK staining is a sensitive and specific marker for secretory carcinoma of the breast.
Abstract PR09: Mammographic breast density and subsequent risk of breast cancer in postmenopausal women according to the status of selected tissue markers: A case-control study
Yaghjyan, Lusine , Pettersson, Andreas , Collins, Laura C. , Schnitt, Stuart J. , Beck, Andrew , Rosner, Bernard , Vachon, Celine M. , Colditz, Graham A. , Vachon, Celine M. , Tamimi, Rulla M.

Mayo Clinic

Cancer Prevention Research | May 9, 2019 | Volume: 6 | Issue: 11_Supplement | Pages: PR09-PR09

10.1158/1940-6215.prev-13-pr09 Get It

Abstract Background: This analysis aimed to determine if associations of prediagnostic mammographic percent breast density, absolute dense area, and absolute non-dense area and risk of breast cancer vary according to the subsequent breast tumors biomarker status. Methods: We included 1,154 postmenopausal women diagnosed with breast cancer between June 1, 1989, and June 30, 2004, and 2,078 matched controls from the Nurses' Health Study I and II. Percent breast density, absolute dense and non-dense areas were estimated from digitized film mammograms using computer assisted thresholding techniques. Density measures were modeled as quartiles. Information on estrogen receptor (ESR1 [ER]), progesterone receptor (PGR [PR]), and human epidermal growth factor receptor 2 (ERBB2 [HER2]) status was obtained from pathology reports and medical records, and if missing, from immunostains performed on paraffin sections of tumor tissue microarrays (TMAs). Other biomarkers assessed on TMAs were androgen receptor (AR), cytokines 5/6 (KRT5/KRT6 [CK5/6]), epidermal growth factor receptor (EGFR), vascular endothelial growth factor (VEGFA [VEGF]), and cyclooxygenase 2 (PTGS2 [COX2]). Information on breast cancer risk factors was obtained prospectively from biennial questionnaires before the date of cancer diagnosis for cases and matched controls. Polychotomous logistic regression was used to assess associations of the three breast density measures with tumor subtypes based on the status of selected tissue markers. Results: Breast cancer risk was positively associated with percent density and absolute dense area and inversely associated with absolute non-dense area (p for trend&lt;0.0001 for all). The associations of percent density with breast cancer risk did not statistically significantly differ by the status of any of the markers. However, we found stronger positive associations for absolute dense area and KRT5/KRT6- and EGFR- tumors as compared to respective marker-positive tumors (4th vs. 1st quartile: OR=2.99 for KRT5/KRT6- vs. OR=0.92 for KRT5/KRT6+ tumors, p-heterogeneity &lt;0.001; OR=3.06 for EGFR- vs. OR=1.08 for EGFR+ tumors, p-heterogeneity=0.001). Stronger inverse associations of absolute non-dense area with breast cancer risk were found for ESR1- as compared to ESR1+ tumors, and for AR+, KRT5/KRT6+, and EGFR+ tumors as compared to respective marker-negative tumors (4th vs. 1st quartile: OR=0.21 for ESR1- vs. OR=0.59 for ESR1+ tumors, p-heterogeneity &lt;0.0001; OR=0.22 for AR+ vs. OR=0.42 for AR- tumors, p-heterogeneity=0.04; OR=0.21 for KRT5/KRT6+ vs. OR=1.14 for KRT5/KRT6- tumors, p-heterogeneity&lt;0.01; OR=0.37 for EGFR+ vs. OR=1.11 for EGFR- tumors, p-heterogeneity&lt;0.01). There were no differences in associations of the density measures with breast cancer by status of other markers evaluated. Conclusions: The findings suggest that some mammographic density measures are differentially associated with the risk of subsequent breast tumor subtypes. Citation Format: Lusine Yaghjyan, Andreas Pettersson, Graham Colditz, Laura Collins, Stuart Schnitt, Andrew Beck, Bernard Rosner, Celine Vachon, Rulla Tamimi. Mammographic breast density and subsequent risk of breast cancer in postmenopausal women according to the status of selected tissue markers: A case-control study. [abstract]. In: Proceedings of the Twelfth Annual AACR International Conference on Frontiers in Cancer Prevention Research; 2013 Oct 27-30; National Harbor, MD. Philadelphia (PA): AACR; Can Prev Res 2013;6(11 Suppl): Abstract nr PR09.